Particulars (Rs. in Crores) | Q1FY23 | Q1FY22 | YoY | Q4FY22 | QoQ |
---|---|---|---|---|---|
Revenue from Operations | 378.79 | 456.78 | -17.10% | 502.35 | -24.60% |
EBITDA | 22.75 | 95.76 | -76.20% | 60.99 | -62.70% |
EBITDA Margin (%) | 6.00% | 21.00% | 12.10% | ||
Profit After Tax | -8.86 | 50.54 | -117.50% | 20.71 | -142.80% |
Net Profit Margin (%) | -2.30% | 11.10% | 4.10% | ||
Earnings Per Share | -0.72 | 4.10 | -117.60% | 1.68 | -142.90% |
Source: Company Filings; StockAxis Research
Highlights for the Quarter Ended June 2022
During the quarter ended June 2022, Hikal posted weak set of numbers, which was
largely expected mainly due to the closure of Taloja plant, which contributes ~15%
to the topline (FY22). However, the plant is fully operational now and we can expect
it to restart contributing from Q2FY22 onwards. Also, the company, during the quarter
faced margin pressure on account of higher input costs. However, the management
said that the prices have started easing out and a positive impact on margins is
expected to be visible in the coming quarters.
The revenue for the quarter was ~Rs. 379 crores, a de-growth of -17.1% YoY and -24.6% QoQ. The crop protection business was impacted due to the closure of Taloja plant. The good part is that the company used the closure period to undertake annual preventive maintenance. The pharmaceuticals segment also witnessed a de-growth of ~18% YoY and ~27% QoQ on the back of temporary demand softening of key products and channel inventory correction by customers.
EBITDA for the quarter was Rs. 23 crores, a decline of 76.2% YoY and 62.7% QoQ and margin also witnessed a contraction by 1,496bps YoY and 613 bps QoQ primarily due to lower sales and product mix, increase in cost of raw materials, energy, and solvents. Further, under absorption of fixed costs during the quarter also reduced the EBITDA. The company bottom line was also impacted. During the Q1FY23, Hikal posted loss of Rs. 8.9 crores vs. profit of Rs. 50.5 crores and Rs. 20.7 crores in Q1FY22 and Q4FY22, respectively.
Key Conference Call Highlights
We believe the company will continue to benefit from its established track record, healthy pipeline of generic APIs, introduction of new products, along with favourable growth prospects for the existing products. It has a healthy pipeline of products under development for proprietary and contract manufacturing, which is expected to support its growth prospects, especially in the export market. The company is in the process to do capex of ~Rs. 600 crores, of which Rs. 273 crores was done in FY22. By FY24/FY25, the business could reach peak utilization which is expected to aid revenue growth.
At CMP of ~Rs. 257, the stock trades at ~11x of FY25E earnings.
Particulars (Rs. in Crores) | Q1FY23 | Q1FY22 | YoY | Q4FY22 | QoQ |
---|---|---|---|---|---|
Revenue from Operations | 378.79 | 456.78 | -17.10% | 502.35 | -24.60% |
COGS | 226.38 | 224.91 | 277.57 | ||
Gross Profit | 152.41 | 231.87 | 224.78 | ||
Gross Profit Margin (%) | 40.20% | 50.80% | 44.70% | ||
Employee Benefit Expenses | 43.21 | 48.09 | 53.62 | ||
Other Expenses | 86.45 | 88.02 | 110.17 | ||
EBITDA | 22.75 | 95.76 | -76.20% | 60.99 | -62.70% |
EBITDA Margin (%) | 6.00% | 21.00% | 12.10% | ||
Depreciation & Amortisation | 26.50 | 22.56 | 24.23 | ||
EBIT | -3.75 | 73.20 | -105.10% | 36.76 | -110.20% |
EBIT Margin (%) | -1.00% | 16.00% | 7.30% | ||
Finance Cost | 11.29 | 7.99 | 8.08 | ||
Other Income | 3.27 | 3.18 | 0.27 | ||
Profit Before Tax | -11.77 | 68.39 | -117.20% | 28.95 | -140.70% |
Tax Expenses | -2.91 | 17.85 | 8.24 | ||
Effective Tax Rate (%) | 24.70% | 26.10% | 28.50% | ||
Profit After Tax | -8.86 | 50.54 | -117.50% | 20.71 | -142.80% |
Net Profit Margin (%) | -2.30% | 11.10% | 4.10% | ||
Earnings Per Share | -0.72 | 4.10 | -117.60% | 1.68 | -142.90% |
Source: Company Filings; StockAxis Research
Year End March (Rs. in Crores) | 2021 | 2022 | 2023E | 2024E | 2025E |
---|---|---|---|---|---|
Net Sales | 1720.44 | 1942.72 | 1954.00 | 2281.50 | 2691.11 |
Growth % | 14.14% | 12.92% | 0.58% | 16.76% | 17.95% |
Expenditure | |||||
Material Cost | 908.38 | 996.39 | 1041.25 | 1192.96 | 1380.23 |
Employee Cost | 164.32 | 203.38 | 212.99 | 223.59 | 242.20 |
Other Expenses | 324.86 | 402.39 | 382.32 | 428.14 | 505.01 |
EBITDA | 322.89 | 340.56 | 317.44 | 436.81 | 563.67 |
EBITDA Margin | 18.77% | 17.53% | 16.25% | 19.15% | 20.95% |
Depreciation & Amortization | 85.25 | 95.67 | 116.29 | 134.53 | 149.73 |
EBIT | 237.64 | 244.89 | 201.15 | 302.28 | 420.96 |
EBIT Margin % | 13.81% | 12.61% | 10.29% | 13.25% | 15.64% |
Other Income | 4.98 | 4.89 | 5.13 | 6.11 | 7.01 |
Interest & Finance Charges | 36.20 | 31.21 | 36.09 | 36.48 | 32.85 |
Profit Before Tax | 206.43 | 218.57 | 170.19 | 271.92 | 388.11 |
Tax Expense | 73.29 | 58.06 | 42.89 | 68.52 | 97.80 |
Effective Tax rate | 35.50% | 26.56% | 25.20% | 25.20% | 25.20% |
Consolidated Net Profit | 133.14 | 160.51 | 127.30 | 203.40 | 290.31 |
Net Profit Margin after MI | 7.74% | 8.26% | 6.51% | 8.91% | 10.79% |
As of March (Rs. in Crores) | 2021 | 2022 | 2023E | 2024E | 2025E |
---|---|---|---|---|---|
Share Capital | 24.66 | 24.66 | 24.66 | 24.66 | 24.66 |
Total Reserves | 908.74 | 1043.32 | 1157.89 | 1338.91 | 1594.38 |
Shareholders' Funds | 933.40 | 1067.98 | 1182.55 | 1363.57 | 1619.04 |
Non Current Liabilities | |||||
Long Term Borrowing | 262.89 | 286.68 | 351.75 | 301.75 | 236.75 |
Current Liabilities | |||||
Short Term Borrowings | 251.43 | 387.76 | 387.76 | 387.76 | 387.76 |
Trade Payables | 229.62 | 249.06 | 256.22 | 232.08 | 258.85 |
Total Equity & Liabilities | 2015.70 | 2213.12 | 2399.91 | 2506.79 | 2724.03 |
Assets | |||||
Net Block | 712.55 | 879.47 | 1043.18 | 1108.65 | 1158.93 |
Current Assets | |||||
Inventories | 266.70 | 328.98 | 330.95 | 342.32 | 398.49 |
Sundry Debtors | 485.53 | 437.72 | 427.04 | 458.36 | 551.76 |
Cash and Bank | 36.81 | 49.09 | 80.88 | 79.60 | 97.00 |
Total Assets | 2015.70 | 2213.12 | 2399.91 | 2506.79 | 2724.03 |
Year End March (Rs. in Crores) | 2021 | 2022 | 2023E | 2024E | 2025E |
---|---|---|---|---|---|
Profit After Tax | 133.14 | 160.51 | 127.30 | 203.40 | 290.31 |
Depreciation | 85.25 | 95.67 | 116.29 | 134.53 | 149.73 |
Changes in Working Capital | -57.89 | 18.69 | 15.87 | -66.83 | -122.80 |
Cash From Operating Activities | 229.02 | 293.73 | 259.46 | 271.09 | 317.24 |
Purchase of Fixed Assets | -157.60 | -273.31 | -280.00 | -200.00 | -200.00 |
Free Cash Flows | 71.42 | 20.42 | -20.54 | 71.09 | 117.24 |
Cash Flow from Investing Activities | 71.42 | 20.42 | -20.54 | 71.09 | 117.24 |
Increase / (Decrease) in Loan Funds | -32.95 | 66.75 | 65.07 | -50.00 | -65.00 |
Equity Dividend Paid | -14.82 | -27.13 | -12.73 | -22.37 | -34.84 |
Cash from Financing Activities | -96.87 | -5.56 | 52.34 | -72.37 | -99.84 |
Net Cash Inflow / Outflow | -24.05 | 3.80 | 31.80 | -1.28 | 17.40 |
Opening Cash & Cash Equivalents | 31.68 | 7.64 | 11.44 | 43.24 | 41.95 |
Closing Cash & Cash Equivalent | 7.64 | 11.44 | 43.24 | 41.95 | 59.35 |
Year End March | 2021 | 2022 | 2023E | 2024E | 2025E |
---|---|---|---|---|---|
Basic EPS | 10.80 | 13.02 | 10.32 | 16.50 | 23.54 |
DPS | 2.00 | 1.60 | 1.03 | 1.81 | 2.83 |
Book value (Rs/share) | 75.70 | 86.62 | 95.91 | 110.59 | 131.31 |
ROCE (%) Post Tax | 17.18% | 15.66% | 11.26% | 15.52% | 19.59% |
ROE (%) | 14.26% | 15.03% | 10.76% | 15.98% | 19.47% |
PE | 13.29 | 30.90 | 24.93 | 15.60 | 10.93 |
P/BV | 1.90 | 4.64 | 2.68 | 2.33 | 1.96 |
EV/EBITDA | 7.25 | 16.51 | 12.19 | 8.64 | 6.55 |
Dividend Yield (%) | 1.39% | 0.40% | 0.40% | 0.71% | 1.10% |
P/Sales | 1.03 | 2.55 | 1.62 | 1.39 | 1.18 |
Net debt/Equity | 0.61 | 0.62 | 0.59 | 0.44 | 0.32 |
Net Debt/ EBITDA | 1.77 | 1.95 | 2.19 | 1.37 | 0.92 |
Sales/Net FA (x) | 2.38 | 2.44 | 2.03 | 2.12 | 2.37 |